# BrightEdge - American Cancer Society

> BrightEdge - American Cancer Society is a VC fund backing Biotechnology. See 24 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Total investments: 24
- Last investment: May 2026
- Lead investor: 0%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/brightedge-acs
- Website: https://www.acsbrightedge.org

BrightEdge - American Cancer Society is a VC fund focused on Biotechnology and Therapeutics. BrightEdge - American Cancer Society focuses on investing in cancer-focused therapies and technologies.

## Contacts

5 contacts available for BrightEdge - American Cancer Society. Shizune tracks 4 team members at BrightEdge - American Cancer Society. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/brightedge-american-cancer-society?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 5 | 21% |
| Therapeutics | 4 | 17% |
| Medical | 3 | 13% |
| Health Care | 2 | 8% |
| Life Science | 2 | 8% |

8 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 3 | 13% |
| Pre-Seed | 1 | 4% |
| Series B | 1 | 4% |
| Series D | 1 | 4% |
| Funding Round | 1 | 4% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 6 | 25% |
| United Kingdom | 1 | 4% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Alice Pomponio | Managing Director | 1 | — |
| Kael Reicin | CFO | 0 | — |
| Stephen Curtis | Sr Director | 1 | — |
| Vadim Shepel | Program Mentor | 0 | — |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| CellCentric | CellCentric’s primary programme targets a deubiquitinase (DUB) enzyme which is strongly associated with prostate cancer, a leading cause of mortality among men. The target modulates the androgen receptor pathway and can potentially combat the multiple resistance mechanisms seen with recently approved prostate cancer drugs such Xtandi and Zytiga.The programme also has potential clinical utility in non-small cell lung, breast and colon cancer. | $220M | Series D | May 06, 2026 |  |
| Deck Bio | Deck Bio develops multi-target T cell engager immunotherapies for solid tumors. | $3.1M | Seed | Apr 09, 2026 |  |
| TippingPoint Biosciences | TippingPoint Biosciences is developing therapeutics that target genome packaging states in diseases like cancer. | $4.5M | Seed | Mar 31, 2026 |  |
| MedHaul | MedHaul is a certified B Corporation and digital health company transforming access to non-emergency medical transportation (NEMT). We help healthcare providers, payers, and clinical trial sponsors easily schedule and manage rides for patients with complex needs, including those requiring wheelchair, stretcher, or door-through-door support.OurAI-driven platform uses predictive analytics to optimize routing, improve patient trust, and reduce costly missed appointments. By addressing transportation barriers, MedHaul helps health systems improve care continuity, strengthen health equity, and ensure that vulnerable populations can reliably access the care they need. |  | Seed | Mar 06, 2026 |  |
| Arul Health | Arul Health is a digital health platform that focuses on emotional and mental support for people affected by cancer. |  | Pre-Seed | Mar 06, 2026 |  |
| PONS | PONS bridges the upstream–downstream imaging gap with patented image enhancement that exposes subtle early-stage tissue shapes and malignant-risk patterns previously invisible to clinicians, and with an AI system for tissue characterization that amplifies ultrasound data size by 50× and optimizes AI systems for diagnostic accuracy. By transforminga single scan into high-resolution, AI-ready insight, PONS enables mass-market, precision ultrasound and accelerates the shift toward decentralized, proactive healthcare. Making ultrasound accessible to the mass market by addressing the limitations of high-resolution images in the early stages of disease. |  | Pre-Seed | Mar 06, 2026 |  |
| Cura Therapeutics | Cura Therapeutics is actively seeking strategic partnering opportunities and collaborations with pharmaceutical and biotechnology companies to develop and commercialize cancer immunotherapies based on multifunctional fusion proteins. Their immunotherapy can be used alone or in combination with a wide range of targeted therapies or cell-basedtherapies such as immune checkpoint inhibitors and CART therapies. |  | Seed | Mar 06, 2026 |  |
| Nemea Therapeutics | Nemea Therapeutics focuses on developing oral small-molecule therapies for aggressive solid tumor. |  | Pre-Seed | Mar 06, 2026 |  |
| MyAtlas | MyAtlas is a mental health app combining AI and neuroscience to deliver precise, personalized behavioral health interventions |  | Pre-Seed | Mar 06, 2026 |  |
| Citrus Oncology, Inc. | Citrus Oncology connects cancer patients, oncology practices, employers, and clinical trialists with experts who manage treatment-related side effects. |  | Pre-Seed | Mar 06, 2026 |  |

10 of 24 investments shown.

## Co-investors
- ScaleHealth — VC Fund, 11 deals together
- [Illumina Ventures](https://shizune.co/investors/profile/illumina-ventures) — VC Fund, 3 deals together
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund, 3 deals together
- [Engine Ventures](https://shizune.co/investors/profile/engine-ventures) — VC Fund, 2 deals together
- [Forbion Capital Partners](https://shizune.co/investors/profile/forbion-capital-partners) — VC Fund, 2 deals together
- [Freeflow Ventures](https://shizune.co/investors/profile/freeflow-ventures) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does BrightEdge - American Cancer Society invest in?

BrightEdge - American Cancer Society invests primarily in Biotechnology, Therapeutics and Medical startups, most often at Seed and Pre-Seed stage. Most of the 24 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact BrightEdge - American Cancer Society?

Public channels for BrightEdge - American Cancer Society include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at BrightEdge - American Cancer Society?

The team at BrightEdge - American Cancer Society includes Alice Pomponio (Managing Director), Kael Reicin (CFO) and Stephen Curtis (Sr Director). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co